Tempest Therapeutics, Inc.
Income Statement
| Line Item | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.0K | $81.0K | $67.0K | $92.0K | $56.0K | $84.0K | $63.0K | $121.0K |
| Cost of Revenue | $44.0K | $54.0K | $112.0K | $218.0K | $29.0K | $274.0K | $269.0K | $1.4M |
| Gross Profit | $11.0K | $27.0K | $-45.0K | $-126.0K | $27.0K | $-190.0K | $-206.0K | $-1.3M |
| Gross Margin | 20.0% | 33.3% | -67.2% | -137.0% | 48.2% | -226.2% | -327.0% | -1,084.3% |
| Operating Expenses | ||||||||
| Research & Development | $1.7M | $2.4M | $2.6M | $3.6M | $4.0M | $5.0M | $5.8M | $4.7M |
| SG&A Expense | $4.2M | $2.6M | $4.2M | $4.8M | $5.1M | $10.8M | $7.1M | $10.9M |
| Operating Income | $-7.8M | $-5.0M | $-4.4M | $-42.4M | $-9.4M | $-17.9M | $-14.6M | $-22.4M |
| Operating Margin | -14,192.7% | -6,155.6% | -6,549.3% | -46,090.2% | -16,796.4% | -21,345.2% | -23,154.0% | -18,486.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-5.7M | $-7.7M | $-7.4M | $-8.5M | $-9.4M | $-18.2M | $-14.9M | $-22.7M |
| Income Tax Expense | $0 | $0 | $0 | $34.0K | $11.0K | $13.0K | $9.0K | $-16.0K |
| Net Income | $-7.5M | $-4.8M | $-4.3M | $-42.1M | $-9.4M | $-18.2M | $-14.9M | $-22.6M |
| Net Margin | -13,701.8% | -5,982.7% | -6,359.7% | -45,793.5% | -16,726.8% | -21,650.0% | -23,642.9% | -18,713.2% |
| EPS (Basic) | $-0.44 | $-0.28 | $-0.25 | $-13.36 | $-0.01 | $-0.02 | $-0.02 | $-0.03 |
| EPS (Diluted) | $-0.44 | $-0.28 | $-0.25 | $-13.36 | $-0.01 | $-0.02 | $-0.02 | $-0.03 |
| Shares Outstanding (Basic) | 859.8M | 858.9M | 858.2M | 857.4M | 856.9M | 856.5M | 855.9M | 855.4M |
| Shares Outstanding (Diluted) | 859.8M | 858.9M | 858.2M | 857.4M | 856.9M | 856.5M | 855.9M | 855.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |